These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 24372893)

  • 21. Economic burden of osteoporosis-related hip fracture in Asia: a systematic review.
    Mohd-Tahir NA; Li SC
    Osteoporos Int; 2017 Jul; 28(7):2035-2044. PubMed ID: 28314898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative study of cost of care of outpatients with bipolar disorder and schizophrenia.
    Somaiya M; Grover S; Chakrabarti S; Avasthi A
    Asian J Psychiatr; 2014 Dec; 12():125-33. PubMed ID: 25246322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cost of schizophrenia: lessons from an international comparison.
    Blomqvist AG; Léger PT; Hoch JS
    J Ment Health Policy Econ; 2006 Dec; 9(4):177-83. PubMed ID: 17200594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indirect health costs in ulcerative colitis and Crohn's disease: a systematic review and meta-analysis.
    Kawalec P; Malinowski KP
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):253-66. PubMed ID: 25656310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-of-illness studies of diabetes mellitus: a systematic review.
    Ng CS; Lee JY; Toh MP; Ko Y
    Diabetes Res Clin Pract; 2014 Aug; 105(2):151-63. PubMed ID: 24814877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The economic burden of visual impairment and blindness: a systematic review.
    Köberlein J; Beifus K; Schaffert C; Finger RP
    BMJ Open; 2013 Nov; 3(11):e003471. PubMed ID: 24202057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health and economic burden of metabolic comorbidity among individuals with bipolar disorder.
    Centorrino F; Mark TL; Talamo A; Oh K; Chang J
    J Clin Psychopharmacol; 2009 Dec; 29(6):595-600. PubMed ID: 19910727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Systematic Review and Critical Appraisal of Economic Evaluations of Pharmacological Interventions for People with Bipolar Disorder.
    Mavranezouli I; Lokkerbol J
    Pharmacoeconomics; 2017 Mar; 35(3):271-296. PubMed ID: 28000158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bipolar disorder--costs and comorbidity.
    Hirschfeld RM; Vornik LA
    Am J Manag Care; 2005 Jun; 11(3 Suppl):S85-90. PubMed ID: 16097719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies.
    Xie F; Kovic B; Jin X; He X; Wang M; Silvestre C
    Pharmacoeconomics; 2016 Nov; 34(11):1087-1100. PubMed ID: 27339668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic Review of the Economic Burden of Pulmonary Arterial Hypertension.
    Gu S; Hu H; Dong H
    Pharmacoeconomics; 2016 Jun; 34(6):533-50. PubMed ID: 26714685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder.
    Dean BB; Gerner D; Gerner RH
    Curr Med Res Opin; 2004; 20(2):139-54. PubMed ID: 15006007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methodological considerations in the assessment of direct and indirect costs of back pain: A systematic scoping review.
    Zemedikun DT; Kigozi J; Wynne-Jones G; Guariglia A; Roberts T
    PLoS One; 2021; 16(5):e0251406. PubMed ID: 33974661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The indirect costs of multiple sclerosis: systematic review and meta-analysis.
    Stawowczyk E; Malinowski KP; Kawalec P; Moćko P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):759-86. PubMed ID: 26189826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic burden of haematological adverse effects in cancer patients: a systematic review.
    Liou SY; Stephens JM; Carpiuc KT; Feng W; Botteman MF; Hay JW
    Clin Drug Investig; 2007; 27(6):381-96. PubMed ID: 17506589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The economic burden of Chagas disease: A systematic review.
    Andrade MV; Noronha KVMS; de Souza A; Motta-Santos AS; Braga PEF; Bracarense H; de Miranda MCC; Nascimento BR; Molina I; Martins-Melo FR; Perel P; Geissbühler Y; Quijano M; Machado IE; Ribeiro ALP
    PLoS Negl Trop Dis; 2023 Nov; 17(11):e0011757. PubMed ID: 37992061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The societal costs and quality of life of patients suffering from bipolar disorder in the Netherlands.
    Hakkaart-van Roijen L; Hoeijenbos MB; Regeer EJ; ten Have M; Nolen WA; Veraart CP; Rutten FF
    Acta Psychiatr Scand; 2004 Nov; 110(5):383-92. PubMed ID: 15458562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidemiology, health-related quality of life and economic burden of binge eating disorder: a systematic literature review.
    Ágh T; Kovács G; Pawaskar M; Supina D; Inotai A; Vokó Z
    Eat Weight Disord; 2015 Mar; 20(1):1-12. PubMed ID: 25571885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-of-illness studies and cost-effectiveness analyses in eating disorders: a systematic review.
    Stuhldreher N; Konnopka A; Wild B; Herzog W; Zipfel S; Löwe B; König HH
    Int J Eat Disord; 2012 May; 45(4):476-91. PubMed ID: 22294558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.